Analysts Set Expectations for Personalis FY2024 Earnings

Personalis, Inc. (NASDAQ:PSNL) – Analysts at HC Wainwright decreased their FY2024 earnings per share (EPS) estimates for Personalis in a research report issued on Monday, January 27th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of ($1.36) for the year, down from their prior estimate of ($1.29). HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Personalis’ current full-year earnings is ($1.37) per share. HC Wainwright also issued estimates for Personalis’ Q4 2024 earnings at ($0.21) EPS, Q1 2025 earnings at ($0.24) EPS, Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.22) EPS, Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at ($0.91) EPS, FY2026 earnings at ($0.71) EPS, FY2027 earnings at ($0.39) EPS and FY2028 earnings at ($0.05) EPS.

Several other equities research analysts have also recently issued reports on the company. Lake Street Capital boosted their price target on Personalis from $7.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. Needham & Company LLC reiterated a “buy” rating and set a $7.25 target price on shares of Personalis in a research report on Wednesday, January 8th.

Personalis Stock Performance

Shares of NASDAQ:PSNL opened at $5.44 on Wednesday. Personalis has a 12-month low of $1.12 and a 12-month high of $7.20. The company’s 50 day moving average price is $4.90 and its two-hundred day moving average price is $4.75.

Personalis (NASDAQ:PSNL) last posted its earnings results on Wednesday, November 6th. The company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.31). Personalis had a negative return on equity of 66.07% and a negative net margin of 104.52%. The firm had revenue of $25.71 million for the quarter, compared to analyst estimates of $20.67 million. During the same period in the prior year, the business posted ($0.51) EPS.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. ARK Investment Management LLC boosted its holdings in shares of Personalis by 11.4% in the 3rd quarter. ARK Investment Management LLC now owns 7,085,523 shares of the company’s stock valued at $38,120,000 after purchasing an additional 723,637 shares in the last quarter. abrdn plc bought a new stake in shares of Personalis during the 4th quarter worth $1,722,000. Walleye Capital LLC bought a new stake in shares of Personalis during the 3rd quarter worth $897,000. Jane Street Group LLC boosted its stake in Personalis by 154.3% in the third quarter. Jane Street Group LLC now owns 164,281 shares of the company’s stock valued at $884,000 after buying an additional 99,671 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in Personalis by 20.0% in the third quarter. Geode Capital Management LLC now owns 498,470 shares of the company’s stock valued at $2,683,000 after acquiring an additional 83,068 shares during the last quarter. 61.91% of the stock is currently owned by institutional investors and hedge funds.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.